Humana Inc. announced that Roy A. Beveridge, M.D. has been appointed Senior Vice President and Chief Medical Officer, effective June 17, 2013. Dr. Beveridge will serve on the company's Executive Team and report to President and Chief Executive Officer Bruce Broussard. He'll be responsible for developing Humana's clinical strategy as well as policies for clinical employees (associates) across Humana's clinical organizations. Dr. Beveridge is currently Chief Medical Officer for McKesson Specialty Health, a subsidiary of McKesson Corporation based in The Woodlands, Tex. Prior to McKesson's acquisition of US Oncology in 2010 he served as the Executive Vice President and Medical Director at US Oncology. Dr. Beveridge was also the Co-Director of the Bone Marrow Transplant Program at INOVA Fairfax Hospital in Falls Church, Virginia.

Humana Inc. announced plans to add approximately 500 Telesales Specialists and leadership jobs nationally to its fulltime Direct Marketing Services (DMS) Telesales workforce. The new jobs will support Humana's DMS retail sales and enrollment operations, and will be located at Humana call centers around the country, including: Madison, Wis. - approximately 60 positions. Miramar, Fla. - approximately 80 positions. Phoenix, Ariz. - approximately 110 positions. San Antonio, Texas - approximately 80 positions. Tampa, Fla. - approximately 170 positions.

Humana Inc. reported earnings results for the first quarter ended March 31, 2013. For the period, the company reported diluted earnings per common share of $2.95, compared to $1.49 per share for the quarter ended March 31, 2012. Results for first quarter of 2013 exceeded management's previous expectations of $1.75 to $1.85 primarily due to outperformance across the company's portfolio of businesses as well as the beneficial effect of certain discrete items and a lower-than-projected tax rate. The company's results for first quarter included the beneficial effect of settlement of contract claims with the Department of Defense related to previously-disclosed litigation and a delay in the implementation of sequestration for the company's Medicare business -- neither of which was anticipated in management's previous financial guidance. The beneficial effect of these items upon first quarter results was approximately $66 million on a pretax basis, or $0.26 per diluted common share. The company revised earnings guidance for the year ending December 31, 2013. For the period, the company expects EPS to be in the range of $8.40 to $8.60 versus management's previous guidance of $7.60 to $7.80. This increase reflects the better-than-expected first quarter results partially offset by higher-than-previously projected investment spending for the company's integrated care delivery model and health care exchanges during the latter half of 2013. The company raised its 2013 full year operating cash flow guidance by $100 million at the midpoint to a range of $1.9 billion to $2.1 billion.